{"Clinical Trial ID": "NCT01129336", "Intervention": ["INTERVENTION 1:", "Patients without bone metastases", "Patients without bone metastases were randomized in a 1:1 to standard treatment ratio plus zoledronic acid 4mg IV The monthly administration of zoledronic acid during months 1-18.", "INTERVENTION 2:", "Patients with bone metastases", "Patients with bone metastases received standard treatment + zoledronic acid for 18 months (discontinuation of disease progression/secondary alignment)"], "Eligibility": ["Incorporation criteria:", "Written consent with knowledge of the case", "Women (aged 18)", "HER2-negative metastatic breast cancer (stage IV)", "Patients will receive chemotherapy or hormonal treatment.", "Patients with newly diagnosed metastatic breast cancer may have received adjuvant or neoadjuvant chemotherapy until treatment has been completed 12 months before relapse.", "If all of the following criteria are met, asymptomatic brain metastasis is allowed:", "No evidence of clinical progression or known progression of brain metastases", "\u2022 Stopping steroids for at least 2 weeks prior to registration for study", "Stable renal function: two serum creatinine determinations of <3 mg/dL obtained at least 7 days apart (a value can be obtained within 6 weeks prior to screening; the second must be obtained during screening).", "ECOG performance status of 0 or 1", "Life expectancy of 6 months", "Negative serum pregnancy test", "Ability and willingness to comply with all requirements of the study", "- Exclusion criteria:", "\u2022 Known hypersensitivity to zoledronic acid or other bisphosphonates", "* Patients with a history of other malignancy in the last two years prior to enrolment, with the exception of basal cell carcinomas cured from the skin or carcinomas excised at the cervical site.", "The simultaneous use of search agents is prohibited. The prior use of search agents is permitted if it is interrupted 30 days prior to screening.", "No previous treatment with antiresorptive agent", "Patients with active brain metastases or meningeal metastases", "\u2022 Severe cardiovascular disease (defined as uncontrolled congestive heart failure), treatment refractory hypertension or poorly controlled type I/II diabetes", "Common active dental problems, including dental abscess or jaw infection (maxilla or mandible) or common or prior diagnosis of osteonecrosis of the jaw", "Patients who have received radiation therapy 4 weeks prior to registration or who have not recovered radiation-related toxicity. Palliative radiation therapy for bone lesions 2 weeks prior to registration is permitted.", "* Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) 4 weeks prior to enrolment in the study or who have not recovered any side effects from such treatment", "\u25cf Renal capacity decreased: creatinine clearance calculated (CrCl) < 30 mL/min (based on Cockcroft-Gault formula)", "- Corrected serum calcium (i.e. adjusted for serum albumin) below 8.0 mg/dL (2.00 mmol/L) or 12 mg/dL (3.00 mmol/L)", "Pregnant or lactating women", "Women of childbearing potential who are not willing/able to use effective contraceptive methods (e.g. abstinence, oral or implant contraceptives, IDU, vaginal or sponge diaphragm, or spermicide condom)", "\u2022 History of non-compliance with medical plans and/or patients considered unreliable", "History of Bone Metabolism Diseases"], "Results": ["Performance measures:", "Number of participants with progression-free survival (PFS)", "Any pathological lymph node (target or non-target) must have shown a reduction in the short axis to < 10 mm. Partial response (PR): a decrease of at least 30% in the sum of the diameters of the target lesions, taking as a reference the base sum of the diameters. Progressive disease (PD): an increase of at least 20% in the sum of the diameters of the target lesions taking as a reference the smallest sum on the study with an absolute increase of at least 5 mm or the appearance of one or more new lesions. Stable disease (SD): neither shrinkage sufficient to qualify for PR nor increase sufficient to qualify for the RFP, taking as a reference the smallest diameters.", "Time limit: up to 18 months", "Results 1:", "Title of the arm/group: Patients without bone metastases", "Description arm/group: Patients without bone metastases were randomized in a 1:1 to standard treatment ratio plus zoledronic acid 4mg IV The monthly administration of zoledronic acid during months 1 to 18.", "Total number of participants analysed: 15", "Type of measurement: Number", "Unit of measure: Participants Event: 9", "Censor: 6", "Results 2:", "Title of arm/group: Patients with bone metastases", "Description of the arm/group: Patients with bone metastases received standard + zoledronic acid treatment for 18 months (discontinuation of disease progression/secondary alignment)", "Total number of participants analysed: 29", "Type of measurement: Number", "Unit of measure: Participants Event: 19", "Censor: 10"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/15 (13.33 per cent)", "Anemia 1/15 (6.67 per cent)", "Rectal haemorrhage 1/15 (6.67 per cent)", "0/15 (0.00 per cent)", "Hepatic impairment 0/15 (0.00 %)", "Extra-dural abscess 0/15 (0.00 %)", "Osteomyelitis 0/15 (0.00 %)", "Pharyngitis 0/15 (0.00 %)", "Pneumonia 0/15 (0.00 %)", "- Sepsis 0/15 (0.00 per cent)", "Diabetes mellitus rate 0/15 (0.00 %)", "Hyperkalaemia 0/15 (0.00 %)", "Hyponatraemia 1/15 (6.67 per cent)", "Adverse Events 2:", "Total: 7/29 (24.14 per cent)", "Anemia 0/29 (0.00 %)", "Rectal haemorrhage 0/29 (0.00 %)", "1/29 (3.45 per cent)", "Hepatic impairment 1/29 (3.45%)", "- Extra-dural abscesses 1/29 (3.45%)", "Osteomyelitis 1/29 (3.45%)", "Pharyngitis 1/29 (3.45%)", "Pneumonia 1/29 (3.45%)", "\u2022 Sepsis 1/29 (3.45 per cent)", "Diabetes mellitus rate 1/29 (3.45%)", "Hyperkalaemia 1/29 (3.45%)", "Hyponatremia 0/29 (0.00 %)"]}